12th Tumor Models Boston

Temas de la conferencia
In the wake of the FDA Modernization Act and translational rates of cancer drugs into the clinic at just 20%, it is critical that oncology scientists invest in more translational and predictive models to de-risk the validation of novel targets, predict therapeutic response, and support biomarker discovery.

Organizador profesional (PCO)
Hanson Wade Group

Observaciones
Brochure: https://go.evvnt.com/2397551-3?pid=4832

Speakers: Alexander Adler, Principal Scientist and Research Associate, Regeneron Pharmaceuticals Inc, Alina Ainbinder, Principal Scientist, Takeda Pharmaceuticals Co. Ltd., and more

https://go.evvnt.com/2397551-2?pid=4832

Mr. Alex Domingo